Attorney Docket No. 18242-511 (VI-0008-P3)

Express Mail No.: EV231271220ÚS of Deposit: July 14, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ICANT(S):

Ackerman et al.

SERIAL NO.:

FILING DATE:

10/036,768

November 6, 2001

EXAMINER:

Jennifer M. Kim

ART UNIT:

1617

FOR:

METHODS AND REAGENTS FOR EXTRACORPOREAL

IMMUNOMODULATORY THERAPY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Response to June 13, 2003 Restriction Requirement (1 pg.);
- Return Postcard. 2.

Applicants believe that no fees are due in connection with this submission. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 18242-511 (VI-0008-P3). A duplicate copy of this Transmittal Letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39.529

David E. Johnson, Reg. No. 41,874

Attorneys for Applicants

c/o MINTZ LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542-6000

Fax: (617) 542-2241

Dated: July 14, 2003

PATENT TRADEMARK OFFICE

Express Mail No.: EV231271220US Daily of Deposit: July 14, 2003

Attorney Docket No. 18242-511 (VI-0008-P3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANT(S):

Ackerman et al.

SERIAL NO.:

10/036,768

EXAMINER:

Jennifer M. Kim'

FILING DATE:

November 6, 2001

ART UNIT:

1617

FOR:

METHODS AND REAGENTS FOR EXTRACORPOREAL

IMMUNOMODULATORY THERAPY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO REQUIREMENT FOR RESTRICTION

In response to the June 13, 2003 Office Action imposuing a requirement for restriction, applicants elect Group I, which contains Claims 1-32, drawn to a method for treating a patient having an immune dysfunction comprising treating peripheral blood mononuclear cells with an aziridino-containing compound, classified in class 514, subclass 183. Applicants also elect species III, drawn to an active agent of formulae II-III (heterocyclic), without traverse. Claims 1-7, 9-20, and 22-32 read on the elected species.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 18242-511 (VI-0008-P3).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,52

Attorney for Applicants

c/o MINTZ LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542-6000 Fax: (617) 542-2241

Dated: July 14, 2003

TRA 1812660v1